LENZ Therapeutics secured official U.S. Food and Drug Administration (FDA) approval for its flagship product VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults. This milestone established VIZZ as the first and only FDA-approved aceclidine-based eye drop designed to improve near vision, triggering immediate commercial launch and distribution preparations across the United States.